Walleye Capital
MED icon

Walleye Capital’s Medifast MED Stock Holding History

Walleye Capital’s Portfolio MED Stock Details MED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17K Buy
+1,600
New +$18.5K ﹤0.01% 4420
2025
Q4 		– Sell
-10,100
Closed -$138K – 4906
2025
Q3 		$138K Buy
10,100
+10,000
+10,000% +$140K ﹤0.01% 3543
2025
Q2 		$1.41K Sell
100
-17,800
-99% -$234K ﹤0.01% 4398
2025
Q1 		$241K Buy
+17,900
New +$269K ﹤0.01% 3119
2024
Q4 		– Sell
-6,100
Closed -$117K – 5260
2024
Q3 		$117K Sell
6,100
-7,400
-55% -$143K ﹤0.01% 4329
2024
Q2 		$295K Buy
13,500
+1,900
+16% +$50.6K ﹤0.01% 3991
2024
Q1 		$445K Buy
+11,600
New +$562K ﹤0.01% 3301
2023
Q4 		– Sell
-3,400
Closed -$254K – 5288
2023
Q3 		$254K Sell
3,400
-5,400
-61% -$479K ﹤0.01% 3366
2023
Q2 		$811K Buy
8,800
+6,500
+283% +$579K ﹤0.01% 2026
2023
Q1 		$238K Buy
2,300
+1,900
+475% +$211K ﹤0.01% 2329
2022
Q4 		$46.1K Buy
+400
New +$46.6K ﹤0.01% 2538
2019
Q3 		– Sell
-1,200
Closed -$154K – 2109
2019
Q2 		$154K Sell
1,200
-2,000
-63% -$278K 0.02% 1070
2019
Q1 		$408K Buy
+3,200
New +$406K 0.07% 464

Other funds holding MED

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCP
Steamboat Capital Partners Rye, New York $468M AUM 80.81% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Walleye Capital's MED Position: Q2 2026 in Review

Walleye Capital increased its Medifast (MED) stake by 145,100% in Q2 2026, buying an estimated $16.7K and bringing the position to 1,452 shares worth $15.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4437.

Walleye Capital first reported a position in MED in Q2 2019 and has held it in 15 quarters since. The position peaked at $2.2M in Q3 2022. 112 funds tracked by Wall St. Rank hold MED as of Q2 2026.

  • Walleye Capital held 1,452 shares of Medifast worth $15.4K as of Q2 2026.
  • Walleye Capital bought 1,451 Medifast shares in Q2 2026, an estimated $16.7K.
  • Medifast made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #4437 holding.
  • Walleye Capital first reported a position in Medifast in Q2 2019 and has held it in 15 quarters since.
  • Walleye Capital's Medifast position peaked at $2.2M in Q3 2022.
  • 112 funds tracked by Wall St. Rank held Medifast as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.